Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

BACKGROUND: Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of these studies was to evaluate the effectiveness of two EGFR-targeted antibody-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res
Hlavní autoři: Zoeller, Jason J., Vagodny, Aleksandr, Daniels, Veerle W., Taneja, Krishan, Tan, Benjamin Y., DeRose, Yoko S., Fujita, Maihi, Welm, Alana L., Letai, Anthony, Leverson, Joel D., Blot, Vincent, Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7708921/
https://ncbi.nlm.nih.gov/pubmed/33256808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01374-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky